Focused on therapies for rare pulmonary and inflammatory diseases, the company develops and commercializes biologic and inhaled treatments targeting high‑unmet‑need conditions. Its lead commercial product, ARIKAYCE, treats refractory Mycobacterium avium complex lung disease, while a broader pipeline...
3 members of Congress have disclosed 11 trades in Insmed Incorporated (INSM), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 9 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-10-03 | Gilbert Cisneros | sell | $1K – $15K |
| 2025-09-22 | Gilbert Cisneros | sell | $1K – $15K |
| 2025-08-08 | Gilbert Cisneros | sell | $1K – $15K |
| 2025-07-07 | Gilbert Cisneros | sell | $1K – $15K |
| 2025-06-16 | Josh Gottheimer | buy | $1K – $15K |
| 2025-04-09 | Josh Gottheimer | sell | $1K – $15K |
| 2024-06-21 | Josh Gottheimer | sell | $1K – $15K |
| 2024-05-28 | Josh Gottheimer | sell | $1K – $15K |
| 2022-12-06 | Josh Gottheimer | buy | $1K – $15K |
| 2020-09-14 | MICHAEL T. MCCAUL | sell | $15K – $50K |
| 2020-03-12 | MICHAEL T. MCCAUL | sell | $1K – $15K |